

Your bridge to

GTACC GTAC TACGTACGTACG' CGTACGTACG'. GTACGTACG. TACGTA TACGTACGTACGTA GTAC' CGTA' GTACC' ACGTACGTACGTAC TACGT GTACG
GTACG GTAC TACGTACGTACG' CGTACGTACGTAC. CGTACGTACGTA GTACGTAC' TACGTACGTACGTAC' GTAC' CGTA' GTACC' ACGTACGTACGTAC TACGT GTAC' GTAC'
TACG' CGTA' TACG' CGTAC' GTACG' ACGTA' CGTA' GTACGTAC' TACGT GTAC' CGTA' GTACC' CGTA' CGTAC' ACGTA'
TACG' ACGT' TACG' CGTAC' GTACG' ACGTA' CGTA' GTACGTAC' TACGT GTAC' CGTA' GTACC' CGTA' CGTAC' ACGTA'
ACGT' ACGT' TACGTACGTACG CGTACGTACGTAC CGTACGTAC CGTA' TACG' TACGT GTAC' CGTA' GTACC' CGTA' GTAC' ACGT'
ACGT' ACGT' TACGTACGTACG CGTACGTACGTAC' TACGTACG'. ACGT' TACG' TACGT GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
CGTA' TACG' TACG' CGTACGTACGTAC' TACGTACG'. ACGT' TACG' TACGT GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
GTAC' TACG' TACG' CGTAC' GTAC' CGTAC' ACGTACGTACGT' TACGT GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
GTACGTAC TACG' CGTAC' GTAC' CGTAC' TACGTACGTACGT' TACGT GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
TACGTAC TACG' CGTAC' GTAC' CGTAC' TACGTACGTACGT' TACGT GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
TACGTA TACGTACGTACGT CGTAC' GTACG' ACGTACGTACGT' TACG' CGTAC' TACG' GTAC' CGTA' GTACC' CGTA' GTACC' ACGTAC'
TACGT' TACGTACGTACGT' CGTAC' GTACG' TACGTACGT' GTAC' TACGTACGTACGT' TACG' CGTA' GTACC' CGTA' GTACC' ACGTAC'

Discover complete workflow offerings and support for whole-exome sequencing.



Anxhela Gustafson, PhD
Scientist
Genomics Institute at Shriners Children's


```

:GTACGTACGTA... TACGTACGTACC... 'ACGT... TACGTACGTAC... 'ACGTACGT... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACG1... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG1... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...
:GTACGTACGTACG... TACGTACGTACGT... 'ACGT... TACGTACGTACGT... 'GTACGTACGTAC... GTACGTACGTACG...

```

from panels to new frontiers of the genome

Exome sequencing is an effective, economical, and efficient approach when whole-genome sequencing is not accessible.



Single platform for




panel designs

Approximately 250 new genes with disease-causing variation are added to the literature annually.¹ This rapid rate of genetic discovery can render current gene panels outdated and incomplete. The subsequent need to update multiple panels on a regular basis can be both labor-intensive and costly. By adopting a whole exome backbone, labs can deliver versatile and comprehensive virtual panels, with simplified workflows and decreased sequencing costs.


Panel testing

- Limited test menus
- Complicated multi assay panel workflows
- Costly and labor-intensive panel update workflow
- Finite ability to discover new genotype-phenotype associations
- Limited re-analysis options



Whole-exome sequencing

- Optimized lab efficiency via assay consolidation
- Single wet lab assay validation, frequent query
- Simplified workflow for panel updates
- Enhanced ability for new discoveries
- Immediate reflex analysis capabilities



All the parts and support from a single

```

:GTACGTACGTACGT :GTACGTACGTAC :CGTAC :ACGT :ACGTACGTAC :ACGTACGTACGTAC :TACGTACGTACGT :CGTACGTACG
:GTACGTACGTACGT :GTACGTACGTAC :CGTAC :ACGT :GTACGTACGTAC :ACGTACGTACGTAC :TACGTACGTACGT :CGTACGTACGTAC
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG
:TACG :GTAC :TACG :CGTAC :ACGT :GTAC :TACG :CGTA :TACG :CGTAC :GTACG

```

partner

Library Preparation



Illumina DNA Prep with Exome 2.5 Plus Enrichment

Combines on-bead tagmentation with built-in library normalization and hybridization enrichment allowing for:

- High level performance with only 50M PE reads
- ~90% Padded Read Enrichment and ~98% Uniformity of Coverage
- ~99% SNV Precision and ~97% SNV recall

Illumina library prep automation protocols are compatible with Beckman Coulter, Eppendorf, Hamilton, PerkinElmer, Tecan, and more. Exome 2.5 Plus may require minor modifications.

Features:

- Flexible and direct DNA input
- Fast, efficient, and reproducible enzyme tagmentation
- Comprehensive exome panel content
- >90% coverage of targets across clinically relevant databases
- Rapid turnaround time from sample to enriched, sequence-ready libraries

Sequencing



NextSeq™ 550 :

Cost-effective benchtop analyzer with:

- ~120 Gb output range
- 400M maximum single-end reads
- 2x150 bp maximum read length
- 5-16 exomes per run*

NextSeq 550 Dx may be used in RUO mode



NovaSeq™ 6000:

Automation- and configuration-friendly system built for deep and broad coverage with:

- 6 Tb maximum output range
- 20B maximum single-end reads
- 2x250 bp maximum read length
- 24-500 exomes per run*

NovaSeq 6000 Dx may be used in RUO mode



NextSeq 1000/2000:

Easy-to-use cartridge-based platform with:

- ~360 Gb maximum output range
- 1.2B maximum single-end reads
- 2x300 bp maximum read length
- 4-48 exomes per run*



NovaSeq X series:

Powerful system for ultra-high-throughput projects:

- 8 Tb† -16 Tb‡ maximum output range
- 26B† - 52B‡ single-end reads
- 2x150 bp maximum read length
- 40-1500 exomes per run*

*depending on flow cell type and desired read depth

† NovaSeq X System

‡ NovaSeq X Plus System

Note: Suggested read-length for WES is 2x101

Data Analysis



Illumina DRAGEN™ Enrichment Pipeline

Accurate, efficient secondary analysis solution for comprehensive variant calling, including SNV, CNV, and SV




Emedgene

Enable high efficiency tertiary analysis for germline research WES, with the support of explainable AI (XAI) and user-configured automation to maximize scale potential

ACGTACGTA, CGTAC, ACGTACG, DGTACGT, ATACGTACGTAC, BTACG, ACGTA, TACGTACGTACGT, DGTAC, DGTAC, TACGT, ATACGT, GTAC, ACGTACGTA,
 GTACGTACGTAC, CGTAC, ACGTACG1, CGTACGT, ATACGTACGTACG1, BTACG, ACGTA, TACGTACGTACGT, GTACG, ACGTA, TACGT, ATACGTA, GTAC, ATACGTACGTAC,
 CGTAC, DGTAC, CGTAC, ACGTACGT, ACGTACGT, ATACG, TACGTA, BTACG, ACGTA, TACGT, TACGT, ATACGTA, GTAC, CGTAC, GTACG,
 CGTAC, ATACG, CGTAC, ACGT/CGT, ACG, ACGT, ATACG, ACGTA, BTACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 CGTAC, ACGT/CGTA, ACG, ACGT, ATACG, ACGTA, BTACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 DGTACGTAC, CGTAC, ACGTA, DGTAC, TACG, ACGT, ATACG, ACGTA, BTACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 TACGTACGTA, CGTAC, ACGTA, GTAC, TAC, ACGT, ATACGTACGTACGT, BTACG, ACGTA, TACGTACGTACGT, GTACGTAC, TACGT, ATACG, ACGT, GTAC, ACGTA, TACGTACG,
 DGTACGTAC, CGTAC, ACGTA, GTAC, TAC, ACGT, ATACGTACGTACG, BTACG, ACGTA, TACGTACGTACGT, GTACGTAC, TACGT, ATACG, ACGT, GTAC, ACGTA, TACGTACG,
 CGTACG, CGTAC, ACGTA, BTACGTAC, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 ATACG, CGTAC, ACGTA, BTACGTAC, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 ACGTA, ATACG, CGTAC, ACGTA, TACGTA, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 CGTAC, DGTACG, CGTAC, ACGTA, TACGTA, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 DGTACGTACGTAC, CGTAC, ACGTA, TACGT, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,
 TACGTACGT, CGTAC, ACGTA, ACGT, ACGT, ATACG, ACGTA, TACGT, TACGT, ATACGTAC, GTAC, ACGTA, TACG,

WES workflows with Illumina Genomics Architecture (IGA)

IGA is a standardized, modular, and flexible framework that streamlines the integration and deployment of NGS by implementing automation-compatible, sample-to-answer workflows through a series of hardware and software.



For more information, visit: <https://support-docs.illumina.com/SHARE/IlluminaGenomicsArchitecture/Content/SHARE/FrontPages/IGA.htm>

Branch out with whole-exome sequencing

Trust Illumina to be your single partner for providing:

- Reagents, instrumentation, and software for data analysis and interpretation
- Fast, easy-to-use, robust assays for high-quality, reproducible results
- World class support for every element of your workflow

Learn more about the power of whole-exome sequencing here:



Scan QR code for more information

<https://www.illumina.com/areas-of-interest/genetic-disease/rare-disease-genomics/targeted-rare-disease-seq.html>

References

1. Seaby EG, Rehm HL, O'Donnell-Luria A. [Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes](#). *Front Genet*. 2021;12. doi:10.3389/fgene.2021.674295.
2. Clark MM, Stark Z, Farnaes L, et al. [Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases](#). *NPJ Genom Med*. 2018;3(1). doi:10.1038/s41525-018-0053-8 2.
3. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. [Ten years of next-generation sequencing technology](#). *Trends Genet*. 2014;30:418-426. doi: 10.1016/j.tig.2014.07.001.
4. Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. [Exome Sequencing: Current and Future Perspectives](#). *G3: Genes/Genomes/Genetics*. 2015;5(8):1543-1550. doi:10.1534/g3.115.018564.

illumina®

1.800.809.4566 toll-free (US) | +1.858.202.4566 tel
techsupport@illumina.com | www.illumina.com

© 2023 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.
M-GL-01485 v2.0